Clinical Trials Browser

Neoplasms, Thyroid Neoplasms

NCT06638931 2026-04-15

ANTARES

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

Clinical Trials

RAISE

ANTARES

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

TROP2

SPARTA

Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma